Zimmer Partners LP Invests $229,000 in Septerna, Inc. (NASDAQ:SEPN)

Zimmer Partners LP purchased a new stake in shares of Septerna, Inc. (NASDAQ:SEPN) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 10,000 shares of the company’s stock, valued at approximately $229,000.

A number of other large investors have also recently added to or reduced their stakes in SEPN. Tower Research Capital LLC TRC purchased a new stake in Septerna in the fourth quarter valued at $25,000. New York State Common Retirement Fund purchased a new stake in Septerna in the 4th quarter valued at about $32,000. Legal & General Group Plc purchased a new stake in Septerna in the 4th quarter valued at about $42,000. Summit Investment Advisors Inc. acquired a new position in Septerna in the fourth quarter valued at about $45,000. Finally, BNP Paribas Financial Markets purchased a new position in Septerna during the fourth quarter worth about $52,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on SEPN shares. Cantor Fitzgerald boosted their price target on shares of Septerna from $20.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, May 16th. Wells Fargo & Company lifted their target price on shares of Septerna from $11.00 to $18.00 and gave the company an “equal weight” rating in a report on Friday, May 16th.

Septerna Price Performance

NASDAQ SEPN opened at $9.42 on Wednesday. The firm has a 50 day simple moving average of $6.55 and a 200-day simple moving average of $14.05. Septerna, Inc. has a one year low of $4.17 and a one year high of $28.99.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). The firm had revenue of $0.22 million during the quarter. Equities research analysts expect that Septerna, Inc. will post -7.11 earnings per share for the current year.

Insiders Place Their Bets

In other Septerna news, Director Alan Ezekowitz acquired 41,355 shares of the stock in a transaction dated Thursday, March 6th. The stock was acquired at an average cost of $6.00 per share, with a total value of $248,130.00. Following the transaction, the director now owns 104,101 shares in the company, valued at $624,606. The trade was a 65.91% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Gil M. Labrucherie acquired 6,282 shares of the company’s stock in a transaction dated Tuesday, February 25th. The stock was acquired at an average price of $5.59 per share, for a total transaction of $35,116.38. Following the acquisition, the chief financial officer now owns 36,282 shares in the company, valued at approximately $202,816.38. The trade was a 20.94% increase in their position. The disclosure for this purchase can be found here. Insiders bought 63,846 shares of company stock worth $381,815 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.